Business Context and Reporting Period
This Form 8-K Current Report was filed by Vivos Therapeutics, Inc. on September 17, 2025. The company is incorporated in Delaware and trades on the NASDAQ Stock Market under the symbol VVOS. The filing is designated as an emerging growth company report.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a material corporate event rather than periodic financial performance data.
Material Changes and Corporate Events
- Item 8.01 Other Information: On September 17, 2025, the Company issued a press release announcing first-time peer-reviewed data.
- Product Validation: The data confirms that Vivos DNA (Daytime-Nighttime Appliance) is both safe and efficacious in treating children suffering from obstructive sleep apnea.
- Exhibit Reference: The full press release is filed as Exhibit 99.1 to this report.
Guidance, Outlook, and Risks
The filing text does not contain specific financial guidance, forward-looking projections, or a detailed discussion of risks and contingencies beyond the announcement of the clinical data. The primary focus is the validation of the Company's core therapeutic product.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the full details of the peer-reviewed data and study parameters.
- Verify the specific journal or publication where the peer-reviewed data was released.
- Assess the potential impact of this safety and efficacy confirmation on future regulatory approvals and commercialization timelines.
- Check subsequent filings for any updates on the Company's cash position, as this 8-K does not disclose current liquidity levels.